Profile
Shelley Kim Fraser worked as a Secretary & Finance Director at hVIVO Ltd.
in 2019.
She also worked as a Finance Director at Organon Pharma (UK) Ltd.
Additionally, she served as the Chief Financial Officer & Director at Induction Healthcare Group Plc from 2019 to 2021.
Former positions of Shelley Kim Fraser
Companies | Position | End |
---|---|---|
INDUCTION HEALTHCARE GROUP PLC | Director of Finance/CFO | 18/01/2021 |
HVIVO PLC | Director of Finance/CFO | 30/07/2019 |
Organon Pharma (UK) Ltd.
Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Director of Finance/CFO | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
INDUCTION HEALTHCARE GROUP PLC | Technology Services |
Private companies | 2 |
---|---|
hVIVO Ltd.
hVIVO Ltd. Miscellaneous Commercial ServicesCommercial Services hVIVO Ltd. engages in the provision of clinical development services with a focus on human disease models. It specializes in human challenge studies using influenza, human rhinovirus, and respiratory syncytial virus for pharmaceutical and biotech companies. The company was founded by John Sidney Oxford in 1989 and is headquartered in London, the United Kingdom. | Commercial Services |
Organon Pharma (UK) Ltd.
Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Shelley Kim Fraser